GeoVax’s (NASDAQ: GOVX) recent appearance in the British Journal of Haematology increasingly resembles the deliberate, early‑stage build‑out of a meaningful new franchise rather than a one‑off academic mention of a new immunotherapy franchise, now reinforced by fresh patent news from the U.S.…